Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 μg in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 12, 2010, Pages 860-867

  Fisher, A ^a   Watling, M ^a   Smith, A ^a   Knight, A ^b  

^a Albert Einstein Centre   (United Kingdom)

^b Somerset House   (United Kingdom)

Author keywords

Analgesics; Cancer pain; Nasal fentanyl; Pectin; Pharmacokinetics

Indexed keywords

FENTANYL CITRATE; NALTREXONE; PECTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RESPIRATION DEPRESSION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 78650820821     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48860     Document Type: Article

References (14)

1. Christrup LL, Foster D, Popper LD et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30: 469-481. (Pubitemid 351483922)
2. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46: 759-770.
3. Darwish M, Kirby M, Robertson P et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin Ther. 2006; 28: 707-14.
4. FDA. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. U.S. Food and Drug Administration. January 2001.
5. Fisher A, Watling M, Smith A et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. 2010; 48: 138-145.
6. Kaasa S, Moksnes K, Nolte T et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag. 2010; 6: 17-27.
7. Kress HG, Oronska A, Kaczmarek Z et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μ g for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009; 32: 1177-1191.
8. Lim SC, Paech MJ, Sunderland VB et al. Pharmacokinetics of nasal fentanyl. J Pharm Practice Res. 2003; 33: 59-63.
9. Lor M, Di Marco M, Marier J et al. Pharmacokinetics, safety and tolerability of a novel 100 mg/h transdermal fentanyl patch co administered with 100 mg oral naltrexone in healthy males. Clin Pharmacol Ther. 2005; 7: P76.
10. Moksnes K, Fredheim OM, Klepstad P et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008; 64: 497-502.
11. Paech MJ, Lim CB, Banks SL et al.Anew formulation of nasal fentanyl spray for postoperative analgesia: a pilot study. Anaesthesia. 2003; 58: 740-744.
12. Portenoy R, Burton A, Gabrail N et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; in press, doi: 10.1016/j.pain.2010. 07.028.
13. Smith BP, Vandenhende FR, DeSante KA et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000; 17: 1278-1283.
14. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20: 87-92.